When Should You Get a Lung Transplant for ILD? Key Signs
At a Glance
People with interstitial lung disease should discuss lung transplant evaluation early, especially when lung function declines, oxygen is newly needed, symptoms worsen, or complications occur. Evaluation is not the same as being placed on the transplant waiting list.
In this answer
4 sections
For people with Interstitial Lung Disease (ILD)—a group of conditions that cause scarring (fibrosis) or inflammation in the lungs—a lung transplant can be a life-extending option when the disease progresses [1]. The most important thing to know is that a transplant evaluation should be considered early [2]. The goal is to get on the radar of a transplant center long before an emergency arises [3]. Getting evaluated does not mean you will be put on a transplant list immediately; rather, it is a proactive step that allows the transplant team to monitor your health and prepare if a transplant becomes necessary down the road [2].
Why Early Referral Matters
Interstitial lung disease can worsen unpredictably [4]. Some forms of the disease, like Idiopathic Pulmonary Fibrosis (IPF) (lung scarring with no known cause) and other Progressive Pulmonary Fibrosis (PPF) (a pattern of worsening scarring that can happen in several types of ILD), can cause lung function to decline over time [5].
If you wait until you are severely ill or experiencing respiratory failure to seek an evaluation, your severe illness may increase surgical risks or make a transplant less feasible [2]. Referring you early gives the transplant center time to assess your overall health, address any potential roadblocks (such as nutrition, heart health, or other medical conditions), and track your disease trajectory [3].
Key Triggers for a Transplant Referral
Your pulmonologist will monitor several indicators to decide when to refer you to a transplant center. According to guidelines from organizations like the International Society for Heart and Lung Transplantation (ISHLT), you should start discussing an evaluation if you experience any of the following:
Declining Lung Function
Pulmonary function tests (PFTs) measure how well your lungs are working. Your team will track:
- Forced Vital Capacity (FVC): The total amount of air you can forcefully exhale. A relative decline of 10% or more in your FVC over time is a strong indicator of disease progression and often prompts listing discussions [4]. However, even an absolute drop of 5% in your FVC percentage over a 6 to 12-month period, when combined with worsening symptoms, shows the disease is progressive and should prompt an early referral [6].
- Diffusing Capacity for Carbon Monoxide (DLCO): A measure of how efficiently gases move from the air sacs in your lungs into your bloodstream [7]. An absolute drop of 10% or more in DLCO is another marker of progression [6].
Increasing Oxygen Needs
You do not need to wait until you are on high amounts of oxygen to get a referral. In fact, any new requirement for supplemental oxygen is often a trigger for a transplant evaluation [1]. If your oxygen saturation drops to 88% or lower during a standardized six-minute walk test, this is a marker of more advanced disease; it should prompt a clinical review of your exertional oxygen needs and a transplant referral discussion [7].
Worsening Symptoms and Complications
Other warning signs include:
- Increasing dyspnea: Feeling significantly more short of breath during your normal daily activities [2].
- Pulmonary hypertension: High blood pressure in the arteries of your lungs, which puts extra strain on your heart [8].
- Hospitalizations: Any hospitalization for a respiratory decline, a pneumothorax (collapsed lung), or an acute exacerbation (a sudden, severe worsening of your breathing) [9].
Safety Warning: If you experience severe breathlessness at rest, blue lips, confusion, chest pain, or rapidly worsening symptoms, seek emergency medical care immediately—do not wait for a transplant consultation.
Evaluation vs. Listing
It is important to understand the difference between being referred for an evaluation and being listed for a transplant [2].
| Transplant Evaluation | Transplant Listing |
|---|---|
| Goal: Determine if you are a potential candidate and establish a baseline. | Goal: Actively wait for a donor lung to become available. |
| When it happens: Early in the disease process, before you are severely ill. | When it happens: When the disease has progressed and the benefits of transplant outweigh the risks. |
| What it involves: Extensive testing of your heart, kidneys, and liver; cancer and infection screenings; review of support systems and financial/insurance logistics. | What it involves: Being placed on an active waiting list (which varies by country, region, and center) based on severity, blood type, and matching criteria. |
| Outcome: You may be followed for months or years before being listed. Some evaluated patients are never listed due to other health factors. | Outcome: You remain on the list until a suitable donor is found, though listing does not guarantee a transplant. |
Being evaluated early ensures that if you do need to be listed, you are already known to the team and optimized for surgery.
What You Can Do Now
While waiting for a referral or evaluation, there are proactive steps you can take:
- Stay Active: Participate in pulmonary rehabilitation if it is available to you, and maintain your nutrition.
- Follow Treatments: Continue taking your prescribed ILD medications and use your oxygen exactly as directed.
- Protect Your Health: Stay up-to-date on vaccinations (flu, pneumonia, COVID-19) and avoid smoking or exposure to secondhand smoke.
Common questions in this guide
When should I ask about a lung transplant if I have ILD?
Does needing oxygen mean I need a lung transplant for ILD?
Which lung-function changes can trigger transplant referral?
What is the difference between transplant evaluation and being listed?
What ILD changes should make me contact my doctor sooner?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What are my current FVC and DLCO numbers (both absolute and relative changes), and how have they trended over the last 6 to 12 months?
- 2.Based on my specific ILD diagnosis and overall health, when would you recommend referring me for a transplant evaluation?
- 3.Are there lifestyle changes or other medical conditions I should address now to improve my transplant candidacy in the future?
- 4.Would a six-minute walk test be helpful right now to assess my exertional oxygen needs and disease severity?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (9)
- 1
Progressive pulmonary fibrosis: an expert group consensus statement.
Rajan SK, Cottin V, Dhar R, et al.
The European respiratory journal 2023; (61(3)) doi:10.1183/13993003.03187-2021.
PMID: 36517177 - 2
Lung transplantation for interstitial lung disease.
Kapnadak SG, Raghu G
European respiratory review : an official journal of the European Respiratory Society 2021; (30(161)) doi:10.1183/16000617.0017-2021.
PMID: 34348979 - 3
Advanced interstitial lung disease: Evidence-based management and clinical approach.
Kattih Z, Greenstein Z, Makkar P, Gupta R
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2025; (42(2)):16206 doi:10.36141/svdld.v42i2.16206.
PMID: 40699491 - 4
Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
Pugashetti JV, Adegunsoye A, Wu Z, et al.
American journal of respiratory and critical care medicine 2023; (207(1)):69-76 doi:10.1164/rccm.202201-0124OC.
PMID: 35943866 - 5
The prognosis of lung transplant candidates with progressive pulmonary fibrosis.
Yamaya T, Muraoka T, Yamaguchi M, et al.
Respiratory investigation 2025; (63(6)):1132-1138 doi:10.1016/j.resinv.2025.09.009.
PMID: 40974786 - 6
Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.
Naqvi M, Hannah J, Lawrence A, et al.
Expert review of respiratory medicine 2024; (18(6)):397-407 doi:10.1080/17476348.2024.2375420.
PMID: 39039699 - 7
Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension.
Alhamad EH, Cal JG, Alrajhi NN, Alharbi WM
Journal of clinical medicine 2020; (9(12)) doi:10.3390/jcm9123828.
PMID: 33255999 - 8
CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis.
Shou AY, Salvatore MM
Clinical imaging 2023; (94()):42-49 doi:10.1016/j.clinimag.2022.11.022.
PMID: 36493681 - 9
Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.
Swaminathan AC, Weber JM, Todd JL, et al.
Respiratory research 2025; (26(1)):73 doi:10.1186/s12931-025-03136-6.
PMID: 40022059
This page is for informational purposes only and does not constitute medical advice about lung transplant timing. Your pulmonologist and transplant team can interpret your test results and recommend the right next steps.
Get notified when new evidence is published on Interstitial lung disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.